Preservation of Islet Function and Glycaemic Control After Total Pancreatectomy with Islet Autotransplantation: Insights From Continuous Glucose Monitoring
Posted inDiabetes & Endocrinology Gastroenterology news

Preservation of Islet Function and Glycaemic Control After Total Pancreatectomy with Islet Autotransplantation: Insights From Continuous Glucose Monitoring

This study demonstrates that nearly half of islet secretory function is preserved following total pancreatectomy with islet autotransplantation (TPIAT), independent of preoperative glycaemic status or prior pancreatic surgery. Continuous glucose monitoring reveals meaningful correlations between islet function and glycaemic control post-TPIAT.
Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: Insights from the MAPLE-HCM Phase 3 Randomized Trial
Posted inCardiology Clinical Updates news

Exercise Performance With Aficamten vs Metoprolol in Obstructive Hypertrophic Cardiomyopathy: Insights from the MAPLE-HCM Phase 3 Randomized Trial

The MAPLE-HCM trial demonstrates aficamten monotherapy significantly outperforms metoprolol in improving exercise capacity, hemodynamics, and patient-reported outcomes in obstructive hypertrophic cardiomyopathy (oHCM), supporting aficamten as a superior first-line therapy.
Long-Term Efficacy and ctDNA Dynamics in Early-Stage ERBB2-Positive Breast Cancer Treated with Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab: Insights from the DAPHNe Trial
Posted innews Oncology Pathology & Lab Medicine

Long-Term Efficacy and ctDNA Dynamics in Early-Stage ERBB2-Positive Breast Cancer Treated with Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab: Insights from the DAPHNe Trial

The DAPHNe trial demonstrates excellent 5-year outcomes for stage II–III ERBB2-positive breast cancer patients treated with an abbreviated neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen, with ultrasensitive ctDNA monitoring showing near-universal clearance post-therapy.